Trial · NCT02879305
Results by group176
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 176
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis | Daprodustat | 11.07 | 95% Confidence Interval 9.98 to 12.26 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis | rhEPO | 11.86 | 95% Confidence Interval 10.72 to 13.09 | Events per 100 person years | |
| Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52) | Daprodustat | 0.28 | Standard Error 0.022 | Grams per deciliter | |
| Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52) | rhEPO | 0.10 | Standard Error 0.022 | Grams per deciliter | |
| Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period: Superiority Analysis | Daprodustat | 11.07 | 95% Confidence Interval 9.98 to 12.26 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period: Superiority Analysis | rhEPO | 11.86 | 95% Confidence Interval 10.72 to 13.09 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period | Daprodustat | 15.84 | 95% Confidence Interval 14.48 to 17.30 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period | rhEPO | 17.85 | 95% Confidence Interval 16.38 to 19.42 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period | Daprodustat | 12.98 | 95% Confidence Interval 11.77 to 14.27 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period | rhEPO | 13.38 | 95% Confidence Interval 12.15 to 14.70 | Events per 100 person years | |
| Mean Average Monthly On-treatment IV Iron Dose Per Participant | Daprodustat | 90.8 | Standard Error 3.34 | Milligrams | |
| Mean Average Monthly On-treatment IV Iron Dose Per Participant | rhEPO | 99.9 | Standard Error 3.35 | Milligrams | |
| Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period | Daprodustat | 8.32 | 95% Confidence Interval 7.39 to 9.32 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period | rhEPO | 8.59 | 95% Confidence Interval 7.65 to 9.62 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period | Daprodustat | 3.31 | 95% Confidence Interval 2.74 to 3.97 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period | rhEPO | 3.46 | 95% Confidence Interval 2.88 to 4.14 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period | Daprodustat | 3.34 | 95% Confidence Interval 2.76 to 4.01 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period | rhEPO | 4.08 | 95% Confidence Interval 3.43 to 4.83 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period | Daprodustat | 1.23 | 95% Confidence Interval 0.89 to 1.66 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period | rhEPO | 1.48 | 95% Confidence Interval 1.10 to 1.94 | Events per 100 person years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02879305/results